Brind.

Pfizer is developing the drug berobenatide for future growth, referencing its 2023 acquisition of Seagen.

Steady: 1 development in the last 24 hours, 1 in the last 7 days Updated 4 hours ago

The latest in this situation

  1. Blackstone has agreed to co-fund the development costs of Pfizer's drug berobenatide.

How it started

3 reports, 1 independent, last reported Sep 7. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Pfizer is developing the drug berobenatide for future growth, referencing its 2023 acquisition of Seagen.

Who's involved

What this event is mainly about
PfizerSeagen

How it developed

Newest first. Tap a step to see who reported it.
  1. Blackstone has agreed to co-fund the development costs of Pfizer's drug berobenatide.Sub-event
  2. Pfizer is advancing berobenatide, a drug developed following the 2023 Seagen acquisition.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story